Literature DB >> 12221867

Treatment of patients with chronic idiopathic urticaria.

Brett E Stanaland1.   

Abstract

Treatment of patients with chronic idiopathic urticaria (CIU) involves reducing symptoms with the least invasive therapy and carefully balancing risk and benefit. The mainstay of therapy is the use of antihistamines with or without the use of intermittent pulses of corticosteroids. Alternative therapies to chronic corticosteroids include leukotriene antagonists, plasma-phoresis, dapsone, stanazolol, hydroxychloroquine, methotrexate, cyclosporin, tacrolimus, and warfarin. A practical approach to CIU bases treatment and severity on the patients' previous response to therapy. Therapy goals are to reduce symptoms until spontaneous resolution occurs. Management of CIU patients can be both frustrating and rewarding.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12221867     DOI: 10.1385/CRIAI:23:2:233

Source DB:  PubMed          Journal:  Clin Rev Allergy Immunol        ISSN: 1080-0549            Impact factor:   8.667


  27 in total

1.  Warfarin treatment of chronic idiopathic urticaria and angio-oedema.

Authors:  R Parslew; D Pryce; J Ashworth; P S Friedmann
Journal:  Clin Exp Allergy       Date:  2000-08       Impact factor: 5.018

Review 2.  Corticosteroids: a review with emphasis on complications of prolonged systemic therapy.

Authors:  A P Truhan; A R Ahmed
Journal:  Ann Allergy       Date:  1989-05

Review 3.  Anti-malarials in dermatology.

Authors:  D Isaacson; M Elgart; M L Turner
Journal:  Int J Dermatol       Date:  1982-09       Impact factor: 2.736

Review 4.  The systemic safety of fexofenadine HCl.

Authors:  J Mason; R Reynolds; N Rao
Journal:  Clin Exp Allergy       Date:  1999-07       Impact factor: 5.018

5.  Effects of fexofenadine, diphenhydramine, and alcohol on driving performance. A randomized, placebo-controlled trial in the Iowa driving simulator.

Authors:  J M Weiler; J R Bloomfield; G G Woodworth; A R Grant; T A Layton; T L Brown; D R McKenzie; T W Baker; G S Watson
Journal:  Ann Intern Med       Date:  2000-03-07       Impact factor: 25.391

6.  Twenty-four hours of activity of cetirizine and fexofenadine in the skin.

Authors:  A Purohit; C Duvernelle; M Melac; G Pauli; N Frossard
Journal:  Ann Allergy Asthma Immunol       Date:  2001-04       Impact factor: 6.347

7.  Delayed pressure urticaria.

Authors:  G L Sussman; R P Harvey; A L Schocket
Journal:  J Allergy Clin Immunol       Date:  1982-11       Impact factor: 10.793

8.  Anti-inflammatory effect of cyclosporin A on human skin mast cells.

Authors:  C Stellato; A de Paulis; A Ciccarelli; R Cirillo; V Patella; V Casolaro; G Marone
Journal:  J Invest Dermatol       Date:  1992-05       Impact factor: 8.551

Review 9.  Cetirizine. A reappraisal of its pharmacological properties and therapeutic use in selected allergic disorders.

Authors:  C M Spencer; D Faulds; D H Peters
Journal:  Drugs       Date:  1993-12       Impact factor: 9.546

10.  Double-blind crossover study comparing doxepin with diphenhydramine for the treatment of chronic urticaria.

Authors:  S L Greene; C E Reed; A L Schroeter
Journal:  J Am Acad Dermatol       Date:  1985-04       Impact factor: 11.527

View more
  2 in total

1.  Use of, satisfaction with, and willingness to switch prescription and over-the-counter treatments for chronic urticaria: an online survey.

Authors:  Donald E Stull; Sonia Gavriel
Journal:  Patient       Date:  2009-09-01       Impact factor: 3.883

Review 2.  Chronic urticaria: aetiology, management and current and future treatment options.

Authors:  Martina M A Kozel; Ruth A Sabroe
Journal:  Drugs       Date:  2004       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.